INDIANAPOLIS, Feb. 14, 2018 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) announced that it will present new data for Taltz® (ixekizumab), baricitinib and mirikizumab at the American Academy of Dermatology (AAD) annual meeting taking place Feb. 16-20, 2018, in San Diego, Calif.
The…
